- Home
- ATRC vs BCAX Comparison
ATRC vs BCAX Comparison
Compare ATRC & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRC
- BCAX
- Stock Information
- Founded
- ATRC 2000
- BCAX 2018
- Country
- ATRC United States
- BCAX United States
- Employees
- ATRC N/A
- BCAX N/A
- Industry
- ATRC Medical/Dental Instruments
- BCAX
- Sector
- ATRC Health Care
- BCAX
- Exchange
- ATRC Nasdaq
- BCAX NYSE
- Market Cap
- ATRC 1.1B
- BCAX 1.0B
- IPO Year
- ATRC 2005
- BCAX 2024
- Fundamental
- Price
- ATRC $35.74
- BCAX $18.09
- Analyst Decision
- ATRC Strong Buy
- BCAX Strong Buy
- Analyst Count
- ATRC 9
- BCAX 4
- Target Price
- ATRC $43.11
- BCAX $41.00
- AVG Volume (30 Days)
- ATRC 736.1K
- BCAX 335.7K
- Earning Date
- ATRC 10-29-2024
- BCAX 11-12-2024
- Dividend Yield
- ATRC N/A
- BCAX N/A
- EPS Growth
- ATRC N/A
- BCAX N/A
- EPS
- ATRC N/A
- BCAX N/A
- Revenue
- ATRC $447,573,000.00
- BCAX N/A
- Revenue This Year
- ATRC $17.75
- BCAX N/A
- Revenue Next Year
- ATRC $13.44
- BCAX N/A
- P/E Ratio
- ATRC N/A
- BCAX N/A
- Revenue Growth
- ATRC 17.56
- BCAX N/A
- 52 Week Low
- ATRC $18.94
- BCAX $17.41
- 52 Week High
- ATRC $42.99
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- ATRC 60.53
- BCAX N/A
- Support Level
- ATRC $34.15
- BCAX N/A
- Resistance Level
- ATRC $36.45
- BCAX N/A
- Average True Range (ATR)
- ATRC 1.35
- BCAX 0.00
- MACD
- ATRC -0.28
- BCAX 0.00
- Stochastic Oscillator
- ATRC 48.31
- BCAX 0.00
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.